Today is Metastatic Breast Cancer Awareness Day, and with the help of theBake It Happencampaign, I’m attacking my frustration two ways I know how, blogging andbaking. What is Bake It Happen? Bake it Happen is a campaign born in 2012 by the daughters of Judy Levin, Shari and Stacy, wh...
October 13 was National Metastatic Breast Cancer Awareness Day. Managing Editor Claire Nixon talks with oncology counselor Sage Bolte, Ph.D., about how to deal with October's pink onslaught if you're living with metastasis and Breastcancer.org Medical Adviser Brian Wojciechowski, M.D., on wher...
Building A Voice for Metastatic Breast Cancer Patients through a Multi-Year Awareness Campaigndoi:10.1016/S0960-9776(17)30666-5FaucetteCraigThe Breast
Sequencing complexities with chemotherapy-based regimens in metastatic breast cancer pose unique challenges for valuebased decision-making in routine practice. Sequencing complexities with chemotherapy-based regimens in metastatic breast cancer (mBC) pose unique challenges for valuebased decision-making in ...
Although 83% of Black patients with metastatic breast cancer expressed interest in clinical trials, only 40% reported having a conversation about enrollment with their health care provider, highlighting one of many potential barriers to achieving clinica
Colorectal Cancer Awareness Month Sections Figures References Abstract Introduction Results Discussion Methods Data availability Code availability References Acknowledgements Author information Ethics declarations Peer review Additional information Supplementary information Source data Rights and permissions About this ar...
The classical understanding of tumor cells induce macrophage polarization via secretion of cytokines or chemokines has been expanded with increasing awareness of exosome-mediated intercellular interactions within the TME [37,38,39]. Exosomes, as carriers of bioactive molecules such as miRNA and proteins,...
Sometimes, I think those of us not living with metastatic breast cancer hesitate to speak out about it for a lot of reasons, primarily perhaps because offear, but also because we don’t think we have the right to do so. We don’t really know what it’s like, so how can speak out...
DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2 prior regimens; results of the primary analysis are publishe...
31. Cortés J, Kim SB, Chung WP, Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer: N Engl J Med, 2022; 386; 1143-54 32. World Health Organization: Technical report: Pricing of cancer medicines and its impacts: A comprehensive technical report for the world health assembly...